Robust Demand for Eli Lilly and Company (LLY)’s Obesity and Diabetes Treatments Drives Strong Investor Sentiment

Faheem Tahir

Thu, February 12, 2026 at 4:26 AM GMT+9 2 min read

In this article:

•                                       StockStory Top Pick 
  

  LLY

  -0.19%

 NVO  

 -0.78%  

Eli Lilly and Company (NYSE:LLY) is included in the list of the best performing S&P 500 stocks in the last five years.

Robust Demand for Eli Lilly and Company (LLY)’s Obesity and Diabetes Treatments Drives Strong Investor Sentiment

As of February 6, 2026, robust demand for the company’s obesity and diabetes treatments continues to drive strong investor sentiment. Eli Lilly and Company (NYSE:LLY)’s shares have gained roughly 70% in the past six months.

According to the company’s press release dated February 4, Eli Lilly and Company (NYSE:LLY) projects revenue of $80.00 to $83.00 billion for 2026, while profit is estimated at $33.50 to $35.00 per share. Beating analyst forecasts, these estimates contrast with rival Novo Nordisk’s expectations of a 5%-13% sales decline amid pricing pressures. As a result of this news, the company’s shares surged 10% in early trading, helping Lilly’s market capitalization hit the $1 trillion mark. The company is the first to achieve this milestone in the pharmaceutical sector.

At the same time, Eli Lilly and Company (NYSE:LLY) reported its Q4 2025 results, with adjusted net income of $7.54 per share, exceeding the $6.67 estimate. Meanwhile, quarterly revenue was $19.30 billion, ahead of the $17.96 billion consensus. The company’s strong performance during the quarter was led by strong sales across Mounjaro ($7.41 billion) and Zepbound ($4.3 billion), driven largely by volume despite price reductions.

Looking ahead, Eli Lilly and Company (NYSE:LLY) said it expects a U.S. launch of orforglipron in the second quarter of 2026, accompanied by an international rollout in 2027.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, and markets pharmaceuticals for diabetes, obesity, oncology, immunology, and neuroscience. The company leverages innovative therapies to address global healthcare needs from its Indianapolis headquarters.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: What Are the Best Stocks to Buy Right Now? and 10 Stocks Under $1 That Will Explode.

Disclosure: None.

Terms and Privacy Policy

Privacy Dashboard

More Info